Presentations and Publications

We share our latest data at medical conferences to showcase our innovative approach to drug discovery and development.

We share our latest data at medical conferences to showcase our innovative approach to drug discovery and development.

Adagrasib
(MRTX849)
PRMT5
(MRTX1719)
KRASG12D
(MRTX1133)
Preclinical
Real World
Data

Adagrasib (MRTX849)

Poster — AACR 2024
Effects of Adagrasib on Cholesterol, Lipid, and Glucose Gene Expression Regulation In Tumor Xenograft Models And Patient Samples
Presentation — AACR 2024
KRYSTAL-1: Pooled Phase 1/2 Efficacy and Safety Data of Adagrasib (MRTX849) in Combination with Cetuximab in Patients with Metastatic Colorectal Cancer (CRC) Harboring a KRASG12C Mutation
Poster — ELCC 2024
Understanding the Real-World (RW) Impact of Time Between Treatment Regimens on Clinical Outcomes in Patients with Metastatic NSCLC Previously Treated with Immunotherapy (IO) in the US Community Oncology Setting
Poster — ISPOR 2023
Matching-Adjusted Indirect Comparison in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer: Adagrasib versus Sotorasib
Poster — ISPOR 2023
Cost per Responder Analysis Comparing Adagrasib and Sotorasib in Patients with KRAS G12C-Mutated Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Presentation — ESMO 2023
Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations
Presentation — ESMO 2023
KRYSTAL-7: Efficacy and Safety of Adagrasib With Pembrolizumab in Patients With Treatment-Naïve, Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a KRASG12C Mutation
Presentation — WCLC 2023
KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients With Advanced/Metastatic KRASG12C-Mutated NSCLC
Research Article — Journal of Clinical Oncology (ascopubs.org)
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C–Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Research Article — Journal of Clinical Oncology (ascopubs.org)
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Presentation — ASCO 2023 April Virtual Plenary
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Harboring a KRASG12C Mutation
Presentation — ELCC 2023
Adagrasib (MRTX849) in Patients with Advanced/Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer (NSCLC): Preliminary Analysis of Mutation Allele Frequency
Research Article — The Oncologist
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
Poster — AACR Special Conference: Targeting RAS
Effects of Adagrasib on Oncogenic Signaling, Immune Cell Regulation and Biomarkers of Response in Preliminary Clinical Analyses
Research Article — The New England Journal of Medicine
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRASG12C
Presentation — ESMO Immuno-Oncology 2022
Preliminary Safety and Efficacy of Adagrasib with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a KRASG12C Mutation
Presentation — ISLB 2022
Clinical Validation of Plasma Cell-Free DNA (cfDNA) Sequencing in a Phase 2 Cohort of the KRYSTAL-1 Study of Adagrasib in Patients with KRASG12C-Mutated NSCLC
Poster — Fourth RAS Initiative Symposium
Effects of Adagrasib on Oncogenic Signaling, Immune Cell Regulation and Biomarkers of Response in Preclinical and Preliminary Clinical Analyses
Poster — ESMO 2022
Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study of Adagrasib (MRTX849) in Patients With KRASG12C-Mutated NSCLC
Presentation — ESMO 2022
KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
Research Article — New England Journal of Medicine, June 2022
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Presentation — ASCO 2022
Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
Presentation — ASCO 2022
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Poster — AACR 2022
KRYSTAL-16: A Phase 1/1b Trial of Adagrasib (MRTX849) in Combination with Palbociclib in Patients with Advanced Solid Tumors with KRASG12C Mutation
Poster — AACR 2022
MRTX849 Inhibits P-gp and Demonstrates CNS Exposure in Mouse Models and Cancer Patients and Demonstrates Anti Tumor Activity in Intracranial Mouse Models of Lung Cancer Brain Metastasis
Research Article — Clinical Cancer Research
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non–Small Cell Lung Cancer
Research Article — Journal of Clinical Oncology
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1) | Journal of Clinical Oncology
Presentation — ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated Activity and Safety of Adagrasib (MRTX849) in Patients (Pts) With Unresectable or Metastatic Pancreatic Cancer (PDAC) and Other Gastrointestinal (GI) Tumors Harboring a KRASG12C Mutation
Poster — ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated Activity and Safety of Adagrasib (MRTX849) in Patients With Unresectable or Metastatic Pancreatic Cancer (PDAC) and Other Gastrointestinal (GI) Tumors Harboring a KRASG12C Mutation
Presentation — ESMO 2021
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
Poster — ESMO GI 2021
KRYSTAL-10: A Randomized Phase 3 Study of Adagrasib (MRTX849) in Combination With Cetuximab vs Chemotherapy in Patients (Pts) With Previously Treated Advanced Colorectal Cancer (CRC) With KRASG12C Mutation
Poster — ASCO 2021
KRYSTAL-12: A Randomized Phase 3 Study of Adagrasib (MRTX849) vs Docetaxel in Patients With Previously Treated Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation
Presentation — ELCC 2021
KRYSTAL-1: Activity and Preliminary Pharmacodynamic (PD) Analysis of Adagrasib (MRTX849) in Patients (PTS) With Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring KRASG12C Mutation
Poster — ASCO GI 2021
KRYSTAL-2 (849-002): Phase 1/2, Open-Label, Multiple-Expansion-Cohort Trial of Adagrasib (MRTX849) + TNO155 (SHP2 Inhibitor) in KRASG12C Solid Tumors
Poster — WCLC 2020
KRYSTAL-7: A Phase 2 Trial of Adagrasib (MRTX849) With Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation
Presentation — EORTC-NCI-AACR 32nd Symposium 2020
KRYSTAL-1: Updated Safety and Efficacy Data With Adagrasib (MRTX849) in NSCLC With KRASG12C Mutation From a Phase 1/2 Study
Presentation — EORTC-NCI-AACR 32nd Symposium 2020
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRASG12C Mutation
Poster — AACR Part II 2020
The anti-tumor activity of the KRASG12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models
Presentation — AACR Part II 2020
Drug-Anchored in vitro and in vivo CRISPR Screens to Identify Targetable Vulnerabilities and Modifiers of Response to MRTX849 in KRASG12C-Mutant Models
Research Article — Journal of Medicinal Chemistry, April 2020
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Research Article — Journal of Internal Medicine, March 2020
Targeting KRASG12C‐Mutant Cancer with a Mutation‐Specific Inhibitor
Poster — 2019 AACR-NCI-EORTC Conference
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment
Poster — 2019 AACR-NCI-EORTC Conference
Discovery and Preclinical Development of MRTX849 A Mutation-Selective KRASG12C Inhibitor
Presentation — 2019 AACR-NCI-EORTC Conference
Pre-Clinical Data Presentation – Christensen – October 2019
Presentation — 2019 AACR-NCI-EORTC Conference
Clinical Data Presentation – Janne – October 2019
Research Article — Cancer Discovery, Oct. 2019
Christensen, J.G. et al, The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients, Cancer Discov October 28 2019 DOI: 10.1158/2159-8290.CD-19-1167
Poster — 2019 ASCO Conference
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRASG12C Mutation
Poster — 2019 AACR Conference
Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257, a Novel KRASG12C Mutant-Selective Small Molecule Inhibitor
Poster — 2018 AACR-RAS Conference
Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRASG12C Inhibitor with Oral Activity in Animal Models of Cancer
Poster — 2018 AACR-RAS Conference
Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257: A Prototype Selective Inhibitor of KRASG12C
Poster — ACS 2018
Structure-Based Drug Discovery of a Selective, Covalent KRASG12C Inhibitor with Oral Activity in Animal Models of Cancer

PRMT5 (MRTX1719)

Poster — AACR 2024
The MTA-cooperative PRMT5 Inhibitor MRTX1719 Demonstrates Increased Anti-Tumor Activity in Combination with KRAS Pathway or Immune Checkpoint Inhibitors in MTAP del Cancers
Research Article — Cancer Discovery | American Association for Cancer Research (aacrjournals.org)
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Research Article — Organic Process Research & Development (acs.org)
Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex
Poster — AACR 2023
Identification of Mechanism-based Combination Targets Effective with the MTA-cooperative PRMT5 Inhibitor MRTX1719 for the Treatment of MTAP Deleted Cancers
Poster — AACR 2023
MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Stabilizes the Ternary PRMT5-MTA Complex and Leads to Synthetic Lethality in MTAP deleted Cancers
Research Article — Journal of Medicinal Chemistry (acs.org), January 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers
Presentation — ENA 2021
MRTX1719: A First-in-class MTA-cooperative PRMT5 Inhibitor that Selectively Elicits Antitumor Activity in MTAP/CDKN2A Deleted Cancer Models
Presentation — AACR 2021
Fragment-based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5•MTA complex and selectively target MTAPDEL tumors

Investigational Use

The efficacy and safety of the investigational compound(s) and/or investigational use(s) described have not been established or approved by the FDA. There is no guarantee the compound(s) will become commercially available for the use(s) under investigation.